The cost effectiveness of influenza vaccination for adults aged 50 to 64 years:: A model-based analysis for Spain

被引:25
作者
Aballea, Samuel
De Juanes, Jose Ramon
Barbieri, Marco
Martin, Monique
Chancellor, Jeremy
Oyagueez, Itziar
Verwee, Bertrand
Largeron, Nathalie
机构
[1] I3 Innovus, Uxbridge UB8 1QG, Middx, England
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
[3] Univ Pompeu Fabra, Barcelona, Spain
[4] Sanofi Pasteur MSD, Madrid, Spain
[5] Sanofi Pasteur, Lyon, France
关键词
influenza; cost effectiveness; Spain;
D O I
10.1016/j.vaccine.2007.07.033
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An economic evaluation of reducing the age threshold for routine influenza vaccination in Spain from 65 to 50 years was performed. A probabilistic model was used to compare a policy based on a recommendation to vaccinate all adults aged 50-64 with the existing vaccination policy for that age group, during interpandemic periods. Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. From TPP perspective, incremental costeffectiveness ratios were estimated at E 14,919 per quality-adjusted life-year (QALY) gained and is an element of 9731 per life-year gained. From societal perspective, the corresponding results were 464149 per QALY and is an element of 2706 per life-year gained. Extending routine influenza vaccination to people over 50 years of age is likely to be cost-effective. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6900 / 6910
页数:11
相关论文
共 46 条
[1]   The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: An international model [J].
Aballea, Samuel ;
Chancellor, Jeremy ;
Martin, Monique ;
Wutzler, Peter ;
Carrat, Fabrice ;
Gasparini, Roberto ;
Toniolo-Neto, Joao ;
Drummond, Michael ;
Weinstein, Milton .
VALUE IN HEALTH, 2007, 10 (02) :98-116
[2]  
[Anonymous], 2003, Health Technol Assess
[3]  
[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001269.PUB2.ART
[4]  
Arrowood JR, 2002, ANN PHARMACOTHER, V36, P1219
[5]   IMPACT OF EPIDEMIC TYPE A INFLUENZA IN A DEFINED ADULT-POPULATION [J].
BARKER, WH ;
MULLOOLY, JP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1980, 112 (06) :798-813
[6]   Effectiveness and cost-benefit of influenza vaccination of healthy working adults - A randomized controlled trial [J].
Bridges, CB ;
Thompson, WW ;
Meltzer, MI ;
Reeve, GR ;
Talamonti, WJ ;
Cox, NJ ;
Lilac, HA ;
Hall, H ;
Klimov, A ;
Fukuda, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (13) :1655-1663
[7]   Cost-effectiveness of the influenza vaccine in a healthy, working-age population [J].
Campbell, DS ;
Rumley, MH .
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1997, 39 (05) :408-414
[8]   Influenza burden of illness - Estimates from a national prospective survey of household contacts in France [J].
Carrat, F ;
Sahler, C ;
Rogez, S ;
Leruez-Ville, M ;
Freymuth, F ;
Le Gales, C ;
Bungener, M ;
Housset, B ;
Nicolas, M ;
Rouzioux, C .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (16) :1842-1848
[9]  
*CLASS COMM WONCA, 1983, ICHPPC 2 DEF INCL CR
[10]  
Cole JA, 2002, CLIN THER, V24, P1824